Physician profile
David Alan Tack
NPI 1124032990
$3,716.83
in general payments reported to CMS, 2019-2025
22 companies · $638 in 2025
The $638 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $750 · 2020: $139 · 2021: $95.94 · 2022: $558 · 2023: $821 · 2024: $715 · 2025: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,010 · Education: $94.99 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $68.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,009.50 |
| Education | $94.99 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $68.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $838.95 | 2019-2025 | Rinvoq |
| Janssen Biotech, INC. | $345.13 | 2020-2025 | Tremfya |
| Genzyme Corporation | $316.10 | 2022-2025 | |
| Lilly USA, LLC | $294.04 | 2019-2024 | Taltz, Olumiant, Zepbound |
| Regeneron Healthcare Solutions, INC. | $271.20 | 2019-2025 | Libtayo, Dupixent |
| Novartis Pharmaceuticals Corporation | $238.77 | 2019-2025 | |
| Leo Pharma INC. | $238.74 | 2019-2024 | Adbry |
| Amgen INC. | $220.83 | 2019-2025 | Otezla, Otezla |
| Ucb, INC. | $179.43 | 2019-2025 | Bimzelx, Cimzia |
| Genentech USA, INC. | $159.04 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $143.67 | 2020-2025 | Ilumya |
| Pfizer INC. | $139.47 | 2019-2024 | |
| Incyte Corporation | $91.84 | 2021-2022 | |
| Stemline Therapeutics INC. | $47.60 | 2019-2025 | Orserdu |
| Organogenesis INC. | $47.18 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $41.00 | 2022-2024 | Sotyktu |
| Dermira, INC. | $26.26 | 2019 | |
| Almirall LLC | $22.97 | 2019 | |
| Dusa Pharmaceuticals, INC. | $16.46 | 2019 | |
| Kyowa Kirin, INC. | $13.30 | 2019 | |
| Arcutis Biotherapeutics, INC. | $12.71 | 2023 | |
| Prugen, INC. Pharmaceuticals | $12.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Tack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.